169 related articles for article (PubMed ID: 2349617)
1. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
Sanz EJ; Bertilsson L
Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
[TBL] [Abstract][Full Text] [Related]
2. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
Spina E; Buemi AL; Sanz E; Bertilsson L
Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
Saner H; Gurtner HP; Preisig R; Küpfer A
Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
[TBL] [Abstract][Full Text] [Related]
4. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
5. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
Küpfer A; Preisig R
Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
Atiba JO; Blaschke TF; Wilkinson GR
Br J Clin Pharmacol; 1989 Aug; 28(2):161-5. PubMed ID: 2775621
[TBL] [Abstract][Full Text] [Related]
8. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
[TBL] [Abstract][Full Text] [Related]
11. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
Dahl ML; Llerena A; Bondesson U; Lindström L; Bertilsson L
Br J Clin Pharmacol; 1994 Jan; 37(1):71-4. PubMed ID: 8148222
[TBL] [Abstract][Full Text] [Related]
12. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
16. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Sanz EJ; Villén T; Alm C; Bertilsson L
Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
[TBL] [Abstract][Full Text] [Related]
17. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
18. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
19. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
Alván G; Bechtel P; Iselius L; Gundert-Remy U
Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
[TBL] [Abstract][Full Text] [Related]
20. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]